Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.

Slides:



Advertisements
Similar presentations
J BERLAND, SAINT-HILAIRE, ROUEN ST+: Stenting après pré-dilataion et ouverture de maille.
Advertisements

A multicenter, randomized, prospective DKCRUSH-III study
BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
BIFURCATION LESIONS Dr. Tahsin.N
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
FFR vs Angiography for Multivessel Evaluation
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
As presented by Keith D Dawkins MD FRCP FACC Southampton University Hospital United Kingdom EuroSTAR The European Cobalt Stent with Antiproliferative for.
A Randomized Comparison of Everolimus-­ Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.
Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Lianglong Chen MD PhD FACC
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
“Randomized Comparison between Sirolimus (Cypher)/Sirolimus-analogous (Xience; Promus) vs. Paclitaxel (Taxus vs.Costar) Eluting Stents in Coronary Lesions:
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
The SAFER Trial Evaluation of the Clinical Safety and Efficacy of the PercuSurge GuardWire in Saphenous Vein Graft Intervention As presented at TCT 2000.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
A Randomized Comparison of
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Disclosures Runlin Gao has received a research grant
Ospedale San Raffaele, Milan, Italy
Runlin Gao, M.D. On behalf of ABSORB China Investigators
Strategy planning in coronary bifurcation stenting
BRS Next Large Trials: What is on the Horizon?
The Tryton Bifurcation Trial:
The DKCRUSH-V Randomized Trial
On behalf of J. Belardi, M. Leon, L. Mauri,
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
SKS Technique Clinical Case
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
Giuseppe Biondi Zoccai, MD
Kyoto University Hospital, Japan
3-Year Clinical Outcomes From the RESOLUTE US Study
ENDEAVOR IV: 5 Year Final Outcomes
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bifurcation Disease: Simulation Training Curriculum
Main branch restenosis at 1 year
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
On behalf of all principal COMPARE II investigators:
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Gregg W. Stone, MD Columbia University Medical Center
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Presentation transcript:

Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang Chen, MD Shao-Liang Chen, MD Gregg W. Stone, MD On Behalf of the DKCRUSH-VI Investigators

Objectives To compare the outcomes of FFR-guided and angiography-guided provisional SB stenting (TAP technique) for true coronary bifurcation lesions

Study design Medina 1,1,1/0,1,1 bifurcation lesions, SB≥2.5 mm FFR group (n=160) Angio group (n=160) Jailed wire, MV Stenting SB FFR 70%, B/C dissection, TIMI<3 If yes, Kissing balloon inflation If still yes, SB Stenting, FKBI 1-year clinical/13-m angio F/U No DKCRUSH-VI study ChicTR-TRC PI: Dr. Shao-Liang Chen Dr. Gregg W Stone 8 centers Independent Committee Core Lab.: CCRF

Major Inclusion criteria ◇ Medina 1,1,1/0,1,1 bifurcation lesions ◇ Side branch ≥2.5 mm in diameter ◇ Lesion length in each branch could be covered by 2 DESs

Exclusion criteria ◇ MI <1 month prior to PCI procedure; ◇ LVEF <30%; eGFR <40 ml/min/1.73 m2; ◇ LMd bifurcation lesion with RCA-CTO not recanalized; ◇ Heavy calcification requiring rotational atherectomy; ◇ Previous CABG or PCI for the target vessel <6-m; ◇ Planned surgical procedure during the first 6-m after enrollment; ◇ Planned surgical procedure during the first 6-m after enrollment; ◇ Stroke within 6 months; ◇ Contraindication or suspected intolerance to any study drug; ◇ Liver dysfunction; pregnancy; expected lifespan of <1 year ◇

Endpoints of the Study ▲ Primary endpoint: composite major adverse cardiac event (MACE), including cardiac death, MI, and TVR ▲ Secondary endpoints: --- cardiac death --- cardiac death --- MI: defined as CK-MB>3-fold the 99% URN --- MI: defined as CK-MB>3-fold the 99% URN --- TLR, CABG, TVR --- TLR, CABG, TVR --- restenosis --- restenosis --- stent thrombosis --- stent thrombosis

Results (1a): Baseline characteristics Angio group (n=160) FFR group (n=160) p MI≥1-m, n (%)25 (15.6)28 (17.5)0.64 Diabetes, n (%)43 (26.9)48 (30)0.62 MVD, n (%)110 (68.7)112 (69.8)0.82 LMd bif., n (%)14 (8.8)15 (9.4)0.68 Medina 1,1,1, n (%)139 (86.8)132 (82.5)0.30 CTO, n (%) MV SB 13 (8.1) 6 (3.8) 14 (8.8) 3 (1.9) TIMI <3, n (%) MV SB 21 (13.1) 5 (3.1) 20 (12.2) 8 (5.0)

Results (1b): Baseline QCA Angio group (n=119) FFR group (n=118) p Main vessel Bifurcation angle  48.8 ± ± Lesion length, mm31.0 ± ± RVD – prox, mm2.94 ± ± DS% – prox55.4 ± ± RVD – distal, mm2.46 ± ± DS% – distal55.9 ± ± Side branch Lesion length, mm12.8 ± ± RVD, mm2.28 ± ± DS%57.8 ± ±

Results (2): Procedural findings FFR group (n=160) Angio group (n=160) Stenting MV 100% Measuring SB-FFR SB stenting in 61 (38.1%) patients Success Failure (n=51, 83.6%) (n=10, 16.4% ) FFR ≥0.8 (n=70) Success (n=145, 90.6%)Failure (n=15) FFR <0.8 (n=75) KBT KBI FFR ≥0.8 FFR<0.8 (n=49 ) (n=26) FFR<0.8(n=4) FFR≥0.8(n=8) Failure(n=3) Stenting SB (success in 22, 77.3%; failure in 8, 22.7%) SB PCI, any: 63.1% SB stenting attempted: 38.1% SB PCI, any: 56.3% SB stenting attempted: 25.9% P=0.07 P=0.01

Results (3): One-year clinical outcomes Angio group (n=160) FFR group (n=160) p Cardiac death, n(%)1 (0.6)2 (1.3)0.56 MI, n(%)22 (13.8)19 (11.9)0.74 TLR, n(%)8 (5.0)5 (3.1)0.57 CABG, n(%) TVR, n(%)11 (6.9)9 (5.6)0.82 MACE, n(%)29 (18.1) 1.00 ST-def/prob, n(%)2 (1.3)1 (0.6)0.56

Results (4): Definition and distribution of restenosis ◇ In both the Angio and FFR groups, ISR in the PMV, DMV and stented SB was defined as a QCA DS >50% ; ◇ In the Angio group, ISR in a non-stented SB was defined as a QCA DS >70%; ◇ In the FFR group, restenosis in a non-stented SB was defined as follow-up FFR <0.80 (i.e. FFR-restenosis). ◇ In a post hoc analysis for all SB lesions, restenosis was defined as a QCA DS >50%.

Distribution of restenosis: Post hoc definition Proximal MV 3.4% Distal MV 9.2% Distal MV 1.7% Side branch 11.8% Proximal MV 1.7% Side branch 21.1% Angiography-guided group FFR-guided group Post hoc analysis of in-segment restenosis* _________________________________________________ Location Angio group FFR group p __________________________________________________ Proximal MV 4 (3.4) 2 (1.7) 0.68 Distal MV 11 (9.2) 2 (1.7) 0.01 Side branch 14 (11.8) 25 (21.2) __________________________________________________ * defined as a QCA DS>50%; Segment=stented+P/D 5-mm MV, main vessel

In conclusion ◇ Based on the results from the current multicenter randomized trial, FFR-guided and angiography-guided provisional stenting of true coronary bifurcation lesions are associated with similar rates of 1-year MACE

Thanks for your attention !